RxDoctor Payments Data

Jessica Chong

Foot & Ankle Surgery · Chino, CANPI 1396021002

Payments from drug & device makers

$2,660in general payments, 2019–2025

Across 100 payments — averaging $26.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medimetriks Pharmaceuticals, Inc.$632
  • Angiodynamics, Inc.$484
  • Paratek Pharmaceuticals, Inc.$434
  • Smith+Nephew$427
  • Amgen$267
  • Cardiovascular Systems Inc.$180
  • plus $236 from 7 others

What the payments were for

  • Consulting fees$35013%
  • Food & beverage$2,31087%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medimetriks Pharmaceuticals, Inc.30$632
Angiodynamics, Inc.5$484
Paratek Pharmaceuticals, Inc.30$434
Smith+Nephew15$427
Amgen(2 entities)3$267
Cardiovascular Systems Inc.3$180
Zyla Life Sciences, Inc.4$62
Melinta Therapeutics, LLC3$53
Sandoz2$36
Sebela Pharmaceuticals Inc.2$36
Zimmer Biomet1$20
Merck1$16
Nabriva Therapeutics, PLC1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,660 in reported general payments places this provider in the 55th percentile of 1,126 foot & ankle surgery providers in California.

See all foot & ankle surgery providers in California

Medicare billing

Part B allowed, 2024
$66,807
Medicare patients
302
Services billed
824

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuzyraOmadacycline Tosylate14$106,136
Ketoconazole960$67,479
Naftifine Hcl175$62,122
MupirocinMupirocin Calcium223$42,568
Oxiconazole Nitrate62$36,645
Tavaborole92$29,926
Ciclopirox333$23,915
Diclofenac Sodium90$12,249
Clotrimazole353$11,334
Econazole Nitrate184$10,185
CiclopiroxCiclopirox Olamine72$4,225
Lidocaine89$3,507
Mupirocin188$1,320
Gentamicin Sulfate11$465
Clindamycin Hcl31$293

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Paratek Pharmaceuticals, Inc.Nuzyra$434$106,13614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,126 foot & ankle surgery providers in California.

Other foot & ankle surgery in Chino

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →